-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $50 Price Target

Benzinga·08/10/2026 10:11:13
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintains $50 price target.